Insider Transactions Reported by 26 Insiders of Ernexa Therapeutics Inc.

Symbol: ERNA, ERNAW on Nasdaq
Location: Cambridge, MA

Quick Takeaways

ERNA - Ernexa Therapeutics Inc. has 26 insiders with reported activity on this page.
Net insider value flow over the last year: +$4,221,826.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: $4,221,826; sell value: $0.
Net share flow: +25,241,163.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to buying over the last 12 months. Net value: +$4,221,826.

Buys

$4,221,826

Shares: 25,241,163

Insiders: 1

Sells

Shares: 0

Insiders: 0

Net

+$4,221,826

Shares: +25,241,163

Insiders: 1

Window (months)	Buy shares	Buy $	Sell $	Net $
0-3	4,000,000	$2,000,000	$0	+$2,000,000
3-6	0	$0	$0	$0
6-9	0	$0	$0	$0
9-12	21,241,163	$2,221,826	$0	+$2,221,826

Ernexa Therapeutics Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Charles Cherington	10%+ Owner	$3,389,720	+$4,221,826	+125%	Filing P/S	10 Feb 2026
Freebird Partners LP	10%+ Owner	$1,503,337			Filing P/S	14 Dec 2023
George P. Denny III	10%+ Owner	$1,134,456			Mixed	02 Dec 2022
John D. Halpern	10%+ Owner	$1,118,891			Mixed	02 Dec 2022
Nicholas J. Singer	Director	$962,330			Mixed	02 Dec 2022
Roger Sidhu	Chief Medical Officer	$200,012			Mixed	20 Sep 2022
Kevin Damour	Chief Scientific Officer	$159,248			Mixed	28 Jun 2022
Sandra M. Gurrola	Sr. VP of Finance	$1,103			Mixed	21 Jun 2025
Andrew C. Jackson	Chief Financial Officer				Mixed	03 Jun 2022
Erich Mohr	Director				Mixed	08 Dec 2021
Howard J. Federoff	CEO & President, Director				Mixed	11 Mar 2022
Erin S. Enright	Director				Mixed	14 Jan 2022
Jay Sial	Chief Administration Officer				Mixed	11 Mar 2022
Luba Greenwood	Director				Mixed	08 Dec 2021
Heather B. Redman	Director				Mixed	14 Jan 2022
Gregory Fiore	Director				Mixed	01 Aug 2022
Dennis Langer	Director				Mixed	08 Dec 2021
William A. Wexler	Director				Mixed	07 Feb 2025
Matthew Angel	President and CEO, Director				Mixed	12 Jan 2023
Elena Ratner	Director				Mixed	13 Jan 2025
Dorothy J. Clarke	General Counsel, Director				Mixed	01 Jan 2024
Peter Cicala	Director				Mixed	07 Feb 2025
Sanjeev Luther	President & CEO, Director				Mixed	07 Feb 2025
Richard W. Wagner	Former director				Mixed	08 Aug 2023
James Arthur Bristol	Director				Mixed	07 Feb 2025
BINDER BRANT	Former director				Mixed	08 Aug 2023

Top shareholders of Ernexa Therapeutics Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Charles Cherington	13D/G 3/4/5	10%+ Owner	35%	10,791,335	$12,949,602	$0	10 Feb 2026	13D/G 3/4/5
Freebird Partners LP	3/4/5 13D/G	10%+ Owner	9.9% from 13D/G	2,774,627 mixed-class rows	$1,503,337	—	14 Dec 2023	3/4/5 13D/G
John D. Halpern	13D/G 3/4/5	10%+ Owner	9.6%	5,971,830	$1,254,084	+$175,402	31 Mar 2025	13D/G 3/4/5
George P. Denny III	3/4/5	10%+ Owner	— class O/S missing	457,442	$1,134,456	—	02 Dec 2022	3/4/5
Nicholas J. Singer	3/4/5 13D/G	Director · Nicholas Jason Singer	4.9% from 13D/G	954,608 mixed-class rows	$962,330	—	02 Dec 2022	3/4/5 13D/G
Shameek Konar	13D/G	—	7.1%	558,531	$720,505	$0	30 Jun 2025	13D/G
IAF, LLC	13D/G	—	4.1%	315,779	$584,191	$0	28 Jul 2025	13D/G
Corient Private Wealth LLC	13F	Company	1.4%	438,092	$525,711	—	31 Dec 2025	13F
Roger Sidhu	3/4/5	Chief Medical Officer	— mixed-class rows	80,650 mixed-class rows	$200,012	—	20 Sep 2022	3/4/5
Kevin Damour	3/4/5	Chief Scientific Officer	— mixed-class rows	64,213 mixed-class rows	$159,248	—	28 Jun 2022	3/4/5
VANGUARD GROUP INC	13F	Company	0.12%	35,922	$43,106	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.08%	23,617	$28,340	—	31 Dec 2025	13F
HRT FINANCIAL LP	13F	Company	0.04%	12,625	$15,000	—	31 Dec 2025	13F
Sippican Capital Advisors	13F	Company	0.03%	10,000	$12,000	—	31 Dec 2025	13F
Sandra M. Gurrola	3/4/5	Sr. VP of Finance	— mixed-class rows	150,110 mixed-class rows	$1,103	—	21 Jun 2025	3/4/5
BlackRock, Inc.	13F	Company	0%	820	$984	—	31 Dec 2025	13F
Fortitude Family Office, LLC	13F	Company	0%	804	$965	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0%	600	$720	—	31 Dec 2025	13F
ASSETMARK, INC	13F	Company	0%	133	$160	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	34	$41	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0%	30	$36	—	31 Dec 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	10	$12	—	31 Dec 2025	13F
MONTAG A & ASSOCIATES INC	13F	Company	0%	8	$10	—	31 Dec 2025	13F
Activest Wealth Management	13F	Company	0%	3	$4	—	31 Dec 2025	13F
Sanjeev Luther	3/4/5	President & CEO, Director	— class O/S missing	1,123,350	—	—	07 Feb 2025	3/4/5
Andrew C. Jackson	3/4/5	Chief Financial Officer	— class O/S missing	664,800	—	—	03 Jun 2022	3/4/5
Howard J. Federoff	3/4/5	CEO & President, Director	— class O/S missing	413,700	—	—	11 Mar 2022	3/4/5
Dorothy J. Clarke	3/4/5	General Counsel, Director	— class O/S missing	168,521	—	—	01 Jan 2024	3/4/5
Gregory Fiore	3/4/5	Director	— class O/S missing	165,800	—	—	01 Aug 2022	3/4/5
Elena Ratner	3/4/5	Director	— class O/S missing	140,078	—	—	13 Jan 2025	3/4/5
Matthew Angel	3/4/5	President and CEO, Director	— class O/S missing	132,003	—	—	12 Jan 2023	3/4/5
William A. Wexler	3/4/5	Director	— class O/S missing	124,533	—	—	07 Feb 2025	3/4/5
Jay Sial	3/4/5	Chief Administration Officer	— class O/S missing	117,200	—	—	11 Mar 2022	3/4/5
BINDER BRANT	3/4/5	Former director	— class O/S missing	83,916	—	—	08 Aug 2023	3/4/5
Richard W. Wagner	3/4/5	Former director	— class O/S missing	83,916	—	—	08 Aug 2023	3/4/5
James Arthur Bristol	3/4/5	Director	— class O/S missing	72,074	—	—	07 Feb 2025	3/4/5
Dennis Langer	3/4/5	Director	— class O/S missing	67,000	—	—	08 Dec 2021	3/4/5
Erich Mohr	3/4/5	Director	— class O/S missing	67,000	—	—	08 Dec 2021	3/4/5
Erin S. Enright	3/4/5	Director	— class O/S missing	67,000	—	—	14 Jan 2022	3/4/5
Heather B. Redman	3/4/5	Director	— class O/S missing	67,000	—	—	14 Jan 2022	3/4/5
Luba Greenwood	3/4/5	Director	— class O/S missing	67,000	—	—	08 Dec 2021	3/4/5
Peter Cicala	3/4/5	Director	— class O/S missing	51,485	—	—	07 Feb 2025	3/4/5

Recent Insider Transactions by Companies or Individuals for Ernexa Therapeutics Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Charles Cherington	ERNA	Common Stock	Purchase	143.9%	$2,000,000	$0.5000	4,000,000	6,779,440	10 Feb 2026	Direct
Charles Cherington	ERNA	Warrants to Purchase Common Stock	Purchase				4,000,000	4,000,000	10 Feb 2026	Direct
Sandra M. Gurrola	ERNA	Common Stock	Options Exercise	37.5%			30	110	21 Jun 2025	Direct
Sandra M. Gurrola	ERNA	Restricted Stock Units	Options Exercise				30	0	21 Jun 2025	Direct
Charles Cherington	ERNA	Common Stock	Purchase	104%	$2,221,826	$0.1046	21,241,163	41,659,743	09 Jun 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.